Merck has signed a licensing agreement worth up to $3.3 billion with Shanghai-based LaNova Medicines to develop, make and ...

A major trial testing multiple sclerosis drug evobrutinib failed in December last year. Merck, which previously predicted ...

This health news summary explores various pharmaceutical developments including Novo Nordisk's phasing out of insulin pens, a ...

At the core of this is a recovery for its life science unit, which dipped last year as its boom from components for Covid ...

BioNTech will make $800mn in upfront payments to Biotheus, a drugmaker based in Guangdong province, with milestone payments of up to $150mn. Uğur Şahin, chief executive of BioNTech, said the company ...

Merck KGaA is a healthcare/pharma company that I have been covering and investing in for about 2 years at this point. Q2 2024 ...

The company saw strong sales from its top-selling cancer drug Keytruda, recently launched treatments and its animal health ...

Overall, the attraction of Pfizer as an investment is its level of diversification with several different growing drug ...

WASHINGTON--Drugmaker Merck asked U.S. regulators Monday ... first pill shown to treat the illness. All other FDA-backed treatments against COVID-19 require an IV or injection.

We recently made a list of UBS’ Best Stocks In The AI, Growth & Low Rates Era: Top 29 US Stocks. In this piece, we will take ...

Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ETCompany ParticipantsYvonne Briggs - Alliance Advisor, ...

Belen Garijo took charge of German drug-to-semiconductor group Merck KGaA with the tailwind of the Covid pandemic, propelling the stock to an all-time high in 2021. Since then, the shares have ...